IL165210A0 - Bazedoxifene treatment regimens - Google Patents

Bazedoxifene treatment regimens

Info

Publication number
IL165210A0
IL165210A0 IL16521004A IL16521004A IL165210A0 IL 165210 A0 IL165210 A0 IL 165210A0 IL 16521004 A IL16521004 A IL 16521004A IL 16521004 A IL16521004 A IL 16521004A IL 165210 A0 IL165210 A0 IL 165210A0
Authority
IL
Israel
Prior art keywords
bazedoxifene
treatment regimens
regimens
treatment
bazedoxifene treatment
Prior art date
Application number
IL16521004A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL165210A0 publication Critical patent/IL165210A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
IL16521004A 2002-06-13 2004-11-15 Bazedoxifene treatment regimens IL165210A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38859602P 2002-06-13 2002-06-13
PCT/US2003/019011 WO2003105834A1 (en) 2002-06-13 2003-06-13 Bazedoxifene treatment regimens

Publications (1)

Publication Number Publication Date
IL165210A0 true IL165210A0 (en) 2005-12-18

Family

ID=29736501

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16521004A IL165210A0 (en) 2002-06-13 2004-11-15 Bazedoxifene treatment regimens

Country Status (20)

Country Link
US (1) US20040063692A1 (es)
EP (1) EP1531807A4 (es)
JP (1) JP2005531613A (es)
KR (1) KR20050010886A (es)
CN (1) CN1658868A (es)
AU (1) AU2003248707A1 (es)
BR (1) BR0311774A (es)
CA (1) CA2489098A1 (es)
CR (1) CR7585A (es)
EC (1) ECSP045492A (es)
IL (1) IL165210A0 (es)
MX (1) MXPA04011634A (es)
NI (1) NI200400065A (es)
NO (1) NO20044954L (es)
NZ (1) NZ537051A (es)
RU (1) RU2355397C2 (es)
SG (1) SG162615A1 (es)
UA (1) UA85374C2 (es)
WO (1) WO2003105834A1 (es)
ZA (1) ZA200409991B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG149081A1 (en) * 2004-01-13 2009-01-29 Wyeth Corp Treatment of aromatase inhibitor therapy-related osteoporosis
RU2400227C2 (ru) * 2004-04-08 2010-09-27 Вайет Состав, содержащий твердую дисперсию базедоксифен ацетата
AU2005233128A1 (en) * 2004-04-08 2005-10-27 Wyeth Bazedoxifene ascorbate as selective estrogen receptor modulator
DE602006010343D1 (de) * 2005-03-31 2009-12-24 Wyeth Corp Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon
JP2008545012A (ja) * 2005-06-29 2008-12-11 ワイス 結合型エストロゲンおよびバゼドキシフェンの医薬処方
EP1919456A2 (en) * 2005-08-24 2008-05-14 Wyeth a Corporation of the State of Delaware Bazedoxifene acetate formulations and manufacturing process thereof
RU2009117201A (ru) * 2006-11-29 2011-01-10 Вайет (Us) Двухслойные таблетки на основе эстрогена/селективного модулятора эстрогенового рецептора и эстрогена/прогестина
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
WO2013182169A1 (en) * 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
KR101940569B1 (ko) * 2017-05-24 2019-01-21 아주대학교산학협력단 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
CN112076163B (zh) * 2019-06-14 2023-06-20 四川科伦药物研究院有限公司 一种醋酸巴多昔芬片的药物组合物及其制备方法
CN113244240A (zh) * 2021-05-26 2021-08-13 深圳市人民医院 醋酸巴多昔芬在治疗急性髓系白血病药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW303299B (es) * 1993-07-22 1997-04-21 Lilly Co Eli
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
DK0802183T3 (da) * 1996-04-19 2002-02-04 American Home Prod Østrogenforbindelser
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6583170B1 (en) * 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
US20020022617A1 (en) * 2000-07-06 2002-02-21 American Home Products Corporation Methods for increasing nitric oxide synthase activity
WO2002003992A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis

Also Published As

Publication number Publication date
JP2005531613A (ja) 2005-10-20
BR0311774A (pt) 2007-05-08
RU2004136316A (ru) 2005-05-10
ECSP045492A (es) 2005-03-10
AU2003248707A1 (en) 2003-12-31
NO20044954L (no) 2004-12-16
MXPA04011634A (es) 2005-07-05
WO2003105834A1 (en) 2003-12-24
UA85374C2 (en) 2009-01-26
KR20050010886A (ko) 2005-01-28
NI200400065A (es) 2005-08-09
ZA200409991B (en) 2007-09-26
EP1531807A4 (en) 2007-10-31
EP1531807A1 (en) 2005-05-25
CN1658868A (zh) 2005-08-24
CR7585A (es) 2008-10-03
US20040063692A1 (en) 2004-04-01
CA2489098A1 (en) 2003-12-24
RU2355397C2 (ru) 2009-05-20
NZ537051A (en) 2007-11-30
SG162615A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
GB0206876D0 (en) Therapeutic agents
GB0229931D0 (en) Therapeutic agents
GB0209991D0 (en) Therapeutic agents
GB0209995D0 (en) Therapeutic agents
GB0209997D0 (en) Therapeutic agents
GB0210127D0 (en) Therapeutic agents
GB0230087D0 (en) Therapeutic agents
AU2003295921A8 (en) Spa apparatus
GB0210124D0 (en) Therapeutic agents
GB0223349D0 (en) Therapeutic agents
GB0230088D0 (en) Therapeutic agents
GB0218526D0 (en) Combination therapy
IL165210A0 (en) Bazedoxifene treatment regimens
GB0218876D0 (en) Therapeutic agents
GB0221574D0 (en) Treatments
GB0217068D0 (en) Therapeutic agents
GB0225501D0 (en) Therapeutic agents
GB0226462D0 (en) Therapeutic agents
GB0208394D0 (en) Therapeutic agents
TW561896U (en) Phototherapy apparatus
AU2003231937A8 (en) Therapeutic methods
GB0225399D0 (en) Therapeutic agents
GB0213493D0 (en) Treatment
GB0220820D0 (en) Treatment
GB0220841D0 (en) Therapy